Skyler B. Johnson, MD


Fellows Can Join the Fight Against Cancer Misinformation Online

Many cancer organizations across the United States and internationally acknowledge a need for in-novative uses of social technology to improve cancer-related support and information provision.

Nathan Bahary, MD, PhD


Dr. Bahary on the Benefits of Ivosidenib in IDH1-Mutated Cholangiocarcinoma

Nathan Bahary, MD, PhD, discusses the benefits of ivosidenib in patients with intrahepatic cholangiocarcinoma whose tumors harbor IDH1 mutations.

Andrea Facciabene, PhD


Dr. Facciabene on Radiation Bridging Therapy Prior to CAR T-Cell Therapy in Mice Models

Andrea Facciabene, PhD, discusses investigating the use of bridging radiation therapy prior to CAR T-cell therapy in mice models.

Daniel Carrizosa, MD, MS


Dr. Carrizosa on the Prevalence of NRG1 Gene Fusions in Solid Tumors

Daniel Carrizosa, MD, MS, discusses the prevalence of NRG1 gene fusions in solid tumors.

Sarki A. Abdulkadir, MD, PhD


Dr. Abdulkadir on the Challenges of Targeting MYC in Prostate Cancer

Sarki A. Abdulkadir, MD, PhD, discusses the challenges of targeting MYC in prostate cancer.

Costanza Lo Cascio, PhD


A New Take on Preclinical Drug Trials for Glioblastoma Treatment

The Ivy Brain Tumor Center at Barrow Neurological Institute in Phoenix, Arizona, is attempting to change the way preclinical studies are developed and conducted to assess the efficacy of drugs for glioblastoma multiforme.

Anita Johnson, MD, FACS


Dr. Johnson on Racial Disparities in Outcomes Across Multiple Tumor Types

Anita Johnson, MD, FACS, discusses racial disparities in outcomes across multiple tumor types.

Krish Patel, MD, Swedish Cancer Institute


Novel Therapies for R/R Follicular Lymphoma

A panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.

Efstathios Kastritis, MD


Dr Kastritis on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis

Efstathios Kastritis, MD, discusses the background of birtamimab and the rationale for investigating the agent in combination with standard-of-care chemotherapy in newly diagnosed patients with Mayo Stage IV amyloid light chain amyloidosis in the phase 3 AFFIRM-AL trial.

Timothy I Shaw, PhD


Dr Shaw on the Heterogeneity Between Paired Primary and Metastatic Solid Tumors

Timothy I Shaw, PhD, discusses the genetic heterogeneity between paired primary and metastatic solid tumors, as well as the implications for neoantigen-based personalized vaccines in cancer care.

Yousef Zakharia, MD


Dr. Zakharia on the Role of Seleno-L-Methionine in Previously Treated Advanced RCC

Yousef Zakharia, MD, discusses the role of seleno-L-methionine in previously treated advanced clear cell renal cell carcinoma.

Nicholas J. Short, MD


Understanding How to Best Measure MRD Negativity in Ph+ ALL

The implementation of treatment with later-generation BCR-ABL1 TKIs like ponatinib and chemotherapy-free combination regimens with blinatumomab plus a TKI have greatly pushed the treatment armamentarium of Philadelphia chromosome–positive acute lymphoblastic leukemia forward.

Ali R. Khaki, MD


Optimizing Therapy for Patients with Advanced Bladder Cancer

Ali R. Khaki, MD, comments on how to treat patients with advanced bladder cancer based on data demonstrated by the EV-103 study of enfortumab vedotin.

Jennifer A. Ligibel, MD


Slow Burn to Wildfire: How Do We Douse the Flames of Burnout in Oncology?

Trauma and stress related to the COVID-19 pandemic, coupled with subsequent widespread labor shortages, have turned burnout, which was an endemic issue in medicine, to a pandemic in health care.

Ryan Haumschild, PharmD, MS, MBA


Future Directions in Precision Medicine: An Evolving Treatment Landscape

Closing out their discussion on biomarkers and precision medicine in cancer care, key opinion leaders look toward future evolutions in the oncology landscape.

Timothy Cloughesy, MD


INDIGO: A Phase 3 Global, Randomized, Double-Blinded Study of Vorasidenib vs Placebo in Patients with Residual or Recurrent Grade 2 Glioma with an IDH1/2 Mutation

Timothy Cloughesy, MD, reviews data from the phase 3 INDIGO trial investigating vorasidenib in patients with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation.

Christian Grohe, MD, Evangelical Lung Cancer Hospital


The Evolving Treatment Landscape of Small Cell Lung Cancer

Closing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.

Aaron Lisberg, MD


Dr Lisberg on Emerging Post-Osimertinib Treatment Options in EGFR-mutant NSCLC

Aaron Lisberg, MD, discusses ongoing and future efforts to expand effective treatment options for patients with osimertinib-resistant, EGFR-mutant non–small cell lung cancer.

Amishi Y. Shah, MD, MD Anderson Cancer Center


Incorporating Treatment Advances Into mRCC Management

Expectations regarding the impact of research in metastatic renal cell carcinoma on the use of immunotherapy and targeted agents in routine clinical practice.

Sajid A Khan MD, FACS, FSSO


Dr. Khan on the Rationale of Examining Disparate Outcomes in GI Tract Cancer Surgery

Sajid A. Khan MD, FACS, FSSO, discusses the rationale of examining disparate outcomes in gastrointestinal tract cancer surgery.

Sophie Paczesny, MD, PhD


The Evolving Field of GVHD Treatment

Sophie Paczesny, MD, PhD, and Yi-Bin Chen, MD, share their expert perspectives on how the GVHD treatment landscape is evolving.

Manojkumar Bupathi, MD, MS


Dr. Bupathi on the Evolving Treatment Landscape of Bladder Cancer

Manojkumar Bupathi, MD, MS, discusses the evolving treatment landscape of bladder cancer.

Bradley J. Monk, MD, FACOG, FACS


Future Outlook of Advanced Ovarian Cancer Treatment

Comprehensive insights on unmet needs, ongoing research, and the future of advanced ovarian cancer treatment.

Melinda L. Telli, MD


The Future of HER2+ Breast Cancer Treatment

Panelists wrap up their discussion on HER2+ breast cancer by summarizing the most exciting recent advances in the field and their hopes for the future of treatment.

Marina Frimer, MD, FACOG, FACS


Dr. Frimer on the Exploration of Maintenance with Niraparib in Uterine Serous Carcinoma

Marina Frimer, MD, FACOG, FACS, discusses the exploration of maintenance with niraparib in a phase 2 trial in patients with advanced or platinum-sensitive recurrent uterine serious carcinoma

Ian Krop, MD, PhD


Dr. Krop on Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer

Ian Krop, MD, PhD, discusses findings from the phase 3 DESTINY-Breast02 trial in patients with HER2-positive metastatic breast cancer.

Horacio J. Asbun, MD


Mapping Progress in Pancreatic Cancer Surgery: Leveraging New Technology

In this last episode of OncChats: Mapping Progress Made in Pancreatic Cancer Surgery, Horacio J. Asbun, MD, and Domenech Asbun, MD, explain how augmented reality or artificial intelligence may be utilized to improve outcomes for patients with pancreatic cancer who are undergoing surgical procedures.

Steven Lee Chang, MD


Dr. Lee on the Rationale for Evaluating Telaglenastat in RCC

Chung-Han Lee, MD, PhD, discusses the rationale for evaluating telaglenastat in renal cell carcinoma.